Activity of Ceftolozane-Tazobactam against Burkholderia pseudomallei
Andrew Slack1, Fiona Parsonson2, Katie Cronin2
1Department of Infectious Disease, Internal Medicine Department, Townsville Hospital, Townsville, Australia.
Abstract:
We investigated the in vitro activity of a novel fifth-generation cephalosporin-tazobactam combination, ceftolozane-tazobactam against Burkholderia pseudomallei, the etiological agent of melioidosis. Using both disc diffusion and minimum inhibitory concentration (MIC) strip techniques against 56 clinical isolates and an national collection of type cultures (NCTC) strain, the MIC to ceftolozane-tazobactam was found to be between 0.75 and 4 mcg/mL. The MIC50 was found to be 1.5 mcg/mL and MIC90 was 2.0 mcg/mL. This study provides initial evidence of ceftolozane-tazobactam as a novel agent in the management of melioidosis.
More Related Videos
12:21The Madagascar Hissing Cockroach as an Alternative Non-mammalian Animal Model to Investigate Virulence, Pathogenesis, and Drug Efficacy
Published on: November 24, 2017
08:31Total Protein Extraction and 2-D Gel Electrophoresis Methods for Burkholderia Species
Published on: October 15, 2013
Related Concept Videos
Co-activators and Co-repressors
tRNA Activation
Activation Energy
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
Secondary Active Transport
Primary Active Transport
